The future of surgery for pancreatic cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Slavin, J ^a   Ghaneh, P ^a   Jones, L ^a   Sutton, R ^a   Hartley, M ^a   Neoptolemos, J P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adjuvant treatment; Gene therapy; Molecular diagnosis; Pancreatectomy; Pancreatic cancer; Prognosis; Surgery

Indexed keywords

ADJUVANT THERAPY; BILIARY TRACT DRAINAGE; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE THERAPY; HUMAN; ONCOGENE K RAS; PALLIATIVE THERAPY; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

EID: 0032794457     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S285     Document Type: Conference Paper

References (104)

1. Gudjonsson B. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg 1495; 181: 483-503.
2. Sauve L. Des pancreaectomies et specialement de la pancreatectomie cephalique. Rev Chir 1908; 37: 335-85.
3. Kausch W. Carcinom der Papilla Duodeni und seine radikale Entfernung. Beitr Klin Chir 1912; 78: 439-86.
4. Whipple AO, Parsons WB, Mullens CR. Treatment of carcinoma of the the ampulla of Vater. Ann Surg 1935; 102: 763-79.
5. Whipple AO. Observations on radical surgery for lesions of pancreas. Surg Gynecol Obstet 1946; 82: 623-31.
6. Bramhall SR, Allum WH, Jones AG et al. Treatment and survival in 13,560 patients with pancreatic cancer and incidence of the disease in the West Midlands: an epidemiological study. Br J Surg 1995; 57: 111-5.
7. Gall FP, Kessler H, Hermanek P. Surgical treatment of ductal pancreatic carcinoma. Eur J Surg Oncol 1991; 17: 173-81.
8. Sperti C, Pasquali C, Piccoli A et al. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996; 83: 625-31.
9. Grace PA, Pitt HA, Tompkins RK et al. Decreased mortality and morbidity after pancreaticoduodenectomy. Am J Surg 1986; 151: 141-9.
10. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987; 206: 358-65.
11. Trede M. Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-58.
12. Yeo JC, Cameron JL, Sohn TA et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Ann of Surg 1997; 226: 248-60.
13. Sosa JA, Bowman HM, Gordon TA et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998; 228: 429-38.
14. Glasgow RE, Mulvihill SJ. Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996; 165: 294-300.
15. Lieberman MD, Kilburn H, Lindsey M et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222: 638-45.
16. Neoptolemos JP, Russell RC, Bramhall S et al. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. Br J Surg 1997; 84: 1370-6.
17. DiCarlo V, Balzano G, Zerbi A et al. Pancreatic cancer resection in elderly patients. Br J Surg 1998; 85: 607-10.
18. Magistrelli P, Masetti R, Coppola R et al. Pancreatic resection for periampullary cancer in elderly patients. Hepato-Gastroenterology 1998; 45: 242-7.
19. Lai EC, Mok FP, Fan ST et al. Preoperative andoscopic drainage for malignant obstuctive jaundice. Br J Surg 1994; 81: 1195-8.
20. Warshaw AL, Gu ZY, Wittenberg J et al. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990; 125: 230-3.
21. Minnard EA, Conlon KL, Hoos A et al. Laparoscopic ultrasound enhances standard laparoscopy in the staging of pancreatic cancer. Ann Surg 1998; 228: 182-7.
22. Legmann P, Vignaux O, Dousset B et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. Am J f Roentgentrerol 1998; 170: 1315-22.
23. McCarthy MJ, Evans J, Sagar G et al. Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg 1998; 85: 320-5.
24. Bluemke DA, Fishman EK. CT and MR evaluation of pancreatic cancer. Surgical Oncology Clinics of North America 1998; 7: 103-24.
25. Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161: 26-9.
26. Finch M, Howes N. Ellis I et al. Hereditary pancreatitis and familial pancreatic cancer. Digestion 1997; 58: 564-9.
27. Lowenfels AB, Maisonneuve P, Dimango EP et al. Hereditary pancreatitis and the risk of pancreatic cancer. Journal of the National Cancer Institute 1997; 89: 442-6.
28. Pellegata NS, Sessa F, Renault B et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and non ductal tumours progress through different genetic lesions. Cancer Research 1994; 54: 1556-60.
29. Hruban RH, van Mansfield ADM, Offerhaus GJA et al. K-ras mutations in adenocarcinoma of the pancreas. Am J Pathol 1993; 143: 545-54.
30. Schaeffer BK, Glasner S, Kuhlmann E et al. Mutated c-K-ras in small pancreatic adenocarcinomas. Pancreas 1994; 9: 161-5.
31. Caldas C, Hahn SA, Hruban RH et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic duct hyperplasia. Cancer Research 1994; 54: 3568-73.
32. Yamanda TM, Nakamori S, Ohzato S et al. Detection of K-Ras mitations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with Clinopathological features. Clinical Cancer Research 1998; 4: 1527-32.
33. Van Laethem JL, Bourgeois V, Parma J et al. Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic disease. Gastrointestinal Endoscopy 1998; 47: 479-85.
34. Furuya N, Kawa S, Akamatsu T et al. Long-term follow up of patients with chronic pancreatitis and k-ras gene mutation detected in pancreatic juice. Gastroenterology 1997; 113: 593-8.
35. Tada M, Ohashi M, Shiratori Y et al. Analysis of K-ras mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996; 110: 227-31.
36. Barton CM, Staddon SL, Hughes CM et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-82.
37. Hahn SA, Schutte ATM, Hoque S et al. DPC4, A candidate tumour suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-43.
38. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics 1994; 8: 27-32.
39. Kawesha A, Ghaneh P, Evans JD et al. Overexpression of C-erbB2, C-erbB3 and cyclin D and loss or inactivation of p53, p16 and p21 WAF1 do not correlate with prognosis in pancreatic cancer. Digestion 1998; 59: 222.
40. Gansauge F, Gansauge S, Schmidt E, et al. Prognostic significance of molecular alterations in human pancreatic carcinoma-an immunological study. Lang Arch Surg 1998; 383: 152-5.
41. Coppola D, Lu L, Fruehauf JP et al. Analysis of p53.p21 (WAF1) and TGF beta 1 in human ductal adenocarcinoma of the pancreas- TGF beta 1 protein expression predicts longer survival. Am J Clin Pathology 1998; 110: 16-23.
42. Friess H, Lu Z, Graber HU et al. Bax but not bcl-2 influences the prognosis of human pancreatic cancer. Gut 1998; 43: 414-21.
43. Evans JD, Cornford PA, Dodson A, et al. Expression of bcl-XL correlates with survival in pancreatic cancer. Int J of Pancreatol 1998; 24:72.
44. Friess H, Zhao L, Andren-Sandberg Å et al. Moderate activation of the apoptosis inhibitor bcl-XL worsens the prognosis in pancreatic cancer. Ann Surg 1998; 228: 780-7.
45. Smith AC, Dowsett JF, Russell RC et al. Randomised trial of endoscopic stealing versus surgical bypass in malignant low bile duct obstruction. Lancet 1994; 344: 1655-60.
46. Anderson JR, Sorensen SM, Kruse A et al. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30: 1132-5.
47. Shepard AH, Royle G, Ross APR. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal bile duct: A randomised trial. Br J Surg 1988; 75: 1166-9.
48. Raiker GK, Melin MN, Ress A et al. Cost effectiveness of surgical palliation versus endoscopic stenting in the management of unresectable pancreatic cancer. Ann Surg Oncol 1996; 3: 470-5.
49. Doller CT. Transluminally-placed coilspring endarterial tube grafts. Invest Radiol 1969; 4: 329.
50. Davids PH, Groen AK, Rauws EAJ et al. Randomised trial of self expanding metal stents for distal malignant biliary obstruction. Lancet 1992; 340: 1488-92.
51. Knyrim K, Wagner HJ, Pausch J et al. A prospective, randomised controlled trial of metal stents for malignant obstruction of the bile duct. Endoscopy 1993; 25: 207-12.
52. Carr-Locke DL, Ball TJ, Conners PJ. Multicenter randomised trial of Wallstent biliary prosthesis versus plastic stents. Gastrointest Endosc 1993; 39:310.
53. Keymling M, Wagener JH, Vakil N et al. Relief of malignant duodenal obstruction by percutaneous insertion of a metal stent. Gastrointest Endosc 1993; 39: 439-41.
54. Tarnasky PR, England RE, Lail LM et al. Cystic duct patency in malignant obstructive jaundice; An ERCP based study relevant to the role of laparoscopic cholecystojejunostomy. Ann Surg 1995; 221: 265-71.
55. Bergamaschi R, Marvik R, Thoresen JE et al. Open versus laparoscopic gastrojejunostomy for palliation in advanced pancreatic cancer. Surg Lap Endosc 1998; 8: 92-6.
56. Jones L, Russell P, Mosca F et al. The Standard Kausch-Whipple Pancreatoduodenectomy. Digestive Surgery 1999 (in press).
57. Harrison LE, Brennan MF. Portal vein resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am 1998; 7: 165-81.
58. Leach SD, Lee JE, Charnsangavej C et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85:611-7.
59. Mayumi T, Nimura Y, Kamiya J et al. Distal pancreatectomy with en bloc resection of the celiac artery for carcinoma of the body and tail of the pancreas. Int J of Pancreatol 1997; 22: 15-21.
60. Watson K. Carcinoma of the ampulla of Vater: successful radical resection. Br J Surg 1944; 31: 368-73.
61. Roder JD, Stein HJ, Huttl W et al. Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 1992; 79: 152-5.
62. Klinkenbijl JH, van der Schelling GP, Hop WC et al. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann of Surg 1992; 216: 142-5.
63. Grace PA, Pitt HA, Longmire WP. Pylorus preserving pancreatoduodenectomy: an overveiw. Br J Surg 1990; 77: 968-74.
64. van Berge Henegouwen MI, Moojen TM, van Gulik TM et al. Postoperative weight gain after standard Whipple's procedure versus pylorus-preserving pancreato-duodenectomynhe influence of tumour status. Br J Surg 1998; 85: 922-6.
65. Brooks JR, Culebras JM. Cancer of the pancreas. Palliative operation, Whipple procedure, or total pancreatectomy? Am J Surg 1976; 131: 516-20.
66. Ihse I, Lilja P, Arnesjo B, Bengmark S. Total pancreatectomy for cancer. An appraisal of 65 cases. Ann Surg 1977; 186: 675-80.
67. Moossa AR, Lewis MH, Mackie CR. Surgical treatment of pancreatic cancer. Mayo Clinic Proceedings 1979; 54: 468-74.
68. van Heerden JA. Pancreatic resection for carcinoma of the pancreas: Whipple versus total pancreatectomy - an institutional perspective. World Journal of Surgery 1984; 8: 880-8.
69. van Heerden JA, McIlrath DC, Ilstrup DM et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas: an update. World Journal of Surgery 1988; 12: 658-62.
70. Cubilla AL, Fortner J, Fitzgerald PJ. Lymph node involvement in carcinoma of nthe head of the pancreas. Cancer 1978; 4: 880-7.
71. Fortner JG, Kim DK, Cubilla A et al. Regional pancreatectomy: en bloc pancreatic, portal vein and lymph node resection. Ann Surg 1977; 186: 42-50.
72. Nimura Y. Pancreatic surgery: cutting-edge developments and technology. Pancreas 1998; 16: 227-32.
73. Mukaiya M, Hirata K, Satoh T et al. Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World Journal of Surgery 1998; 22: 248-52.
74. Hirata K, Sato T, Mukaiya M et al. Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 1997; 132: 771-6.
75. Nagakawa T, Nagamori M, Futakami F et al. Results of extensive surgery for pancreatic carcinoma. Cancer 1996; 77: 640-5.
76. Henne-Bruns D, Kremer B, Meyer-Pannwitt U et al. Partial duodenopancreatectomy with radical lymphadenectomy in patients with pancreatic and periampullary carcinomas: initial results. Hepato-Gastroenterology 1993; 40: 145-9.
77. Pedrazzoli S, DiCarlo V, Dionigi R et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. Ann Surg 1998; 228: 508-17.
78. Neoptolemos JP, Bramhall S, Kerr DJ. Adjuvant treatment in pancreatic cancer: combined treatment modalities. In: Beger HG. Warshaw A, Carr-Locke DC, Russell RCG, Büchler M, Neoptolemos JP, Sarr M (Eds) The Pancreas. Boston. Blackwell Scientific 1998: 1104-19.
79. Moertel CG, Childs DS, Reitermeier RJ et al. Combined 5-flourouracil and supervoltage radium therapy of locally unresectable gastrointestinal cancer. Lancet 1969; ii: 865-7.
80. Cullinan S, Moertel CG, Wieand HS et al. A phase III trial on the therapy of advanced pancreatic carcinoma: evaluation of the Mallinson regime and combined 5-flourouracil, doxorubicin and cisplatinum. Cancer 1990; 65: 2207-12.
81. Gastrointestinal Tumour Study Group. Therapy of locally unresectable pancreatic carcinoma: a randomised comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads) and high dose radiation and 5-flourouracil. Cancer 1981; 48: 1705-10.
82. Gastrointestinal Tumour Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006-10.
83. Jeekel J. Adjuvant or neoadjuvant therapy for pancreatic carcinoma? Digestion 1997; 58: 533-5.
84. Bakkevold KE, Arneso B, Dhal O et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater; results of a prospective, randomised multi-center study. Eur J Surg 1993; 29: 698-703.
85. Neoptolemos JP, Kerr DJ, Beger H et al. ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 1997; 58: 570-7.
86. Matrisan L. Metalloproteinases and their inhibitors in matrix remodelling. Trends in Genetics 1990; 6: 1-8.
87. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991 1991; 64: 327-36.
88. Mollenhauer J, Roether I, Kern HF. Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumour cell proliferation in vitro. Pancreas 1987; 2: 14-24.
89. Evans JD, Ghaneh P, Kawesha A et al. Role of matrix metalloproteinases and their inhibitors in pancreatic cancer. Digestion 1997; 58: 520-8.
90. Bramhall S, Neoptolemos JP, Stamp G et al. Inbalance of expression of matrix metalloproteinases (MMPs) in human pancreatic cancer. J Pathology 1997; 182: 347-55.
91. Evans JD, Bramhall SR, Carmichael J et al. A phase II trial of marimastat (BB-2516) in advanced pancreatic cancer. Ann Oncol 7 1996: Supple 5: A239P.
92. Bouvet M, Bold RJ, Lee J et al. Adenovirus mediated wild type p53 tumour suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998; 5: 681-688.
93. Green NK, Youngs DJ, Neoptolemos JP et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinilrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997; 4: 229-38.
94. Yoshida Y, Tasaki K, Kimurai M et al. Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T cells. Anticancer Res 1998; 18: 333-5.
95. Geer RJ, Brennan MF. Prognostic indicators of survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68-72.
96. Nitecki SS, Sarr MG, Colby TV et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66.
97. Russell RCG. Unusual pancreatic tumours. In Neoptolemos JP, Lemoine NR, eds. Pancreatic Cancer: Molecular and Clinical Advances, Vol. 308-207. Oxford: Blackwell Science Publications, 1996.
98. Mosca F, Giulianotti PC, Balestracci T et al. Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 1997; 122: 553-66.
99. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg 1984; 199: 418-25.
100. Manabe T, Ohshio G, Baba N et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989; 64: 1132-7.
101. Hiraoka T. Extended radical resection of cancer of the pancreas with intraoperative radiotherapy. Baillieres Clinical Gastroenterology 1990; 4: 985-93.
102. Ishikawa O, Ohhigashi H, Sasaki Y et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988; 208: 215-20.
103. Hanyu F, Imaizumi T, Suzuki N et al. Extended radical Whipple resection for carcinoma of the head of the pancreas. In: Reber HA, ed. Pancreatic carcinoma. New Jersey: Humana Press Inc. 1998: 201-12.
104. Naganuma T, Kararada Y. Extended pancreatic resection for carcinoma of the pancreas. In: Reber HA, (Ed) Pancreatic Carcinoma. New Jersey: Humana Press Inc. 1998: 213-33.